ImmunityBio, Inc. - Common Stock (NQ:IBRX)

10.29 +1.01 (+10.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Dow Drops 1%; US Producer Prices Rise In April ↗

May 11, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping over 1% on Thursday. Following the market opening Thursday, the Dow traded down 1.15% to 33,144.32 while the NASDAQ fell 0.17% to...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 11, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 08, 2023

Via Benzinga

The 7 Most Undervalued Growth Stocks for Your May Buy List ↗

May 08, 2023

Economic data and a short-covering rally suggest that the outlook for undervalued growth stocks is improving.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 05, 2023

Via Benzinga

Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 04, 2023

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 89.3% to $7.44.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 04, 2023

Via Benzinga

Zillow, Shopify, Datadog And Other Big Stocks Moving Higher On Thursday ↗

May 04, 2023

U.S. stocks traded lower, with the Dow Jones falling around 400 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome

April 25, 2023

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University

April 24, 2023

From ImmunityBio, Inc.

Via Business Wire

Super Micro Computer, Garrett Motion, Rackspace Technology And Other Big Stocks Moving Lower On Monday ↗

April 24, 2023

U.S. stocks traded mixed, with the Nasdaq Composite dropping around 50 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

3 Stocks to Buy That Could Be the Next Biotech Breakthrough ↗

April 16, 2023

Biotech stocks are highly speculative, but it's possible to choose ones with excellent risk-reward ratios.

Via InvestorPlace

Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 17, 2023

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 13, 2023

Via Benzinga

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 13, 2023

Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 21, 2023

Via Benzinga

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 21, 2023

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 02, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

February 28, 2023

During Tuesday, 79 stocks hit new 52-week lows.

Via Benzinga

ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU

February 16, 2023

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

February 15, 2023

From ImmunityBio, Inc.

Via Business Wire

Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 15, 2023

Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.

Via Benzinga

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

January 19, 2023

From ImmunityBio, Inc.

Via Business Wire

Tesla, Hyzon Motors And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 29, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

December 12, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference

November 17, 2022

From ImmunityBio, Inc.

Via Business Wire

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer

November 10, 2022

From ImmunityBio

Via Business Wire

ImmunityBio to Participate in the Jefferies London Healthcare Conference

October 27, 2022

From ImmunityBio, Inc.

Via Business Wire

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.